On the TA front, VIT back to re-test support - break this and low 20s incoming.The FA conundrum is that FY23 results will look good but is it deceiving?When your established competitors (EBO, API, SIG) are operating at 10% Gross Margin to VITs >30% then they're going to come for your lunch.At an annualised cost base of $20m (VIT had $10m below the line expenses for HY) it means $100m revenue is actually loss-making at 10% GM.GM at 10% requires revenue of $200m to B/E.So is it a value trap?
Ann: Vitura Health joining S&P/ASX All Ordinaries Index, page-92
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
